Quick Facts

• May help address mild to moderate pain.
• May contribute to reducing high temperature (fever).
• Indicated for conditions such as headache, cold and flu symptoms, toothache, and post-immunisation fever.

Calpol 6 plus is a supportive option indicated for the temporary management of mild to moderate pain and for its potential to reduce fever (high temperature). It contains the active ingredient paracetamol, which is widely recognized for its analgesic and antipyretic properties. The medication may be used to help ease discomfort associated with various common conditions in children aged six years and over.

Key therapeutic domains include providing relief for symptoms like headache, earache, sore throat, and toothache. It is also an acceptable choice for managing general aches, pains, and the fever that can follow routine immunisation. The use of paracetamol in these contexts is widely utilized for the symptomatic support of patients. The medication’s primary function is to offer symptomatic comfort in these situations.

Who Can and Cannot Use Calpol 6 Plus? — Official Regulatory Information

The eligibility profile for Calpol 6 Plus Oral Suspension is defined strictly by age restrictions, known allergies, and specific underlying health conditions, as mandated by regulatory authorities.

Age-Group and General Eligibility

Population Status	Regulatory Rule
Recommended Use	Children 6 years of age and over, including adolescents and adults.
Not Recommended Use	Children under 6 years of age (specific to this high-strength formulation).
Pregnancy and Lactation	Pregnancy: Use is acceptable only if clinically needed, using the lowest effective dose. Lactation: Use is not contraindicated.

---

Contraindications and Restrictions

Use of this medicine is contraindicated in patients with a known hypersensitivity to the active ingredient, paracetamol, or any of its excipients. It is also strictly contraindicated for patients with hereditary fructose intolerance due to the presence of sorbitol/maltitol.

Conditional Use is advised for patients with existing medical conditions that may affect drug clearance or toxicity risk. This includes individuals with severe hepatic impairment (liver problems), severe renal impairment (kidney problems), chronic alcoholism, malnutrition, or sepsis. Additionally, use requires caution in patients with Gilbert’s Syndrome.

Interactions with other medicines and products

Calpol 6 Plus contains Paracetamol, and its official interaction profile is defined by regulatory guidelines focusing on specific co-administration risks.

Prohibited and High-Risk Combinations

Co-administration with any other medicinal product containing paracetamol or acetaminophen is strictly prohibited to prevent the risk of accidental overdose. Prolonged, regular use alongside anticoagulants, such as Warfarin, is formally documented to enhance the anticoagulant effect, creating an increased risk of bleeding. Specific mandatory timing rules apply to high-risk substances: the product is advised to be avoided for 72 hours before and during treatment with Busulfan.

Exposure and Metabolic Alterations

The drug’s exposure is modified by several substances. Medicines like Metoclopramide and Domperidone are noted to increase the speed of paracetamol absorption. Conversely, Cholestyramine reduces absorption if administered within one hour. Substances that induce liver enzymes, including certain antiepileptics (e.g., Carbamazepine, Phenytoin) and the herbal product St. John's Wort, increase the hazard of toxicity due to enhanced metabolic byproducts. Concurrent intake with Flucloxacillin is associated with a risk of High Anion Gap Metabolic Acidosis, a risk heightened in populations with severe renal impairment. Chronic alcohol ingestion also officially increases the risk of paracetamol hepatotoxicity.

The mechanism of action for Paracetamol (the active ingredient in Calpol 6 Plus) involves multiple intersecting pathways predominantly focused on the central nervous system ( CNS) .

Inhibition of Central PGE2 Synthesis and Thermoregulation

This mechanistic domain focuses on the drug's primary action on the Cyclooxygenase ( COX) enzyme pathway within the CNS and spinal cord. Paracetamol acts as a reducing co-substrate for the COX peroxidase function, which specifically interferes with the necessary chemical processes that lead to the formation of prostaglandin E2 ( PGE2) in the brain. This action modulates key pathways by lowering PGE2 levels in the hypothalamic thermoregulation center. This physiological consequence lowers the body’s temperature set point, which functionally activates physiological heat loss mechanisms, such as sweating and vasodilation.

Modulation of Nociception via Endocannabinoid Pathways

The drug’s analgesic action is reinforced by a secondary pathway involving its metabolite, AM404. After formation, AM404 modulates signaling by activating Transient Receptor Potential Vanilloid-1 ( TRPV1) channels and indirectly enhancing the Cannabinoid Receptor Type 1 ( CB1) system in the brain and spinal cord. This process affects systems where specific neurotransmitters and pain mediators dominate. By initiating or suppressing signaling sequences in these nociceptive pathways, the mechanism results in the suppression of afferent nociceptive signal conduction to the brain.

How to Use Calpol 6 plus (Official Administration Guidelines)

Calpol 6 Plus is a paracetamol oral suspension for use in children aged 6 years and over. Administration guidelines provide the specific volumes, frequency, and preparation steps for proper use.

Administration Scope

Feature	Official Instruction
Route of Administration	Restricted to Oral administration only.
Dosing Schedule	Volume is determined by age band: 6 to 8 years (5 mL); 8 to 10 years (7.5 mL); 10 to 12 years (10 mL); 12 to 16 years (10 mL to 15 mL).
Frequency & Interval	Maximum of 4 doses in any 24-hour period. A minimum of 4 hours must separate each dose.
Preparation	The bottle must be shaken well for at least 10 seconds before the dose is measured.
Measurement	The dose must be accurately measured using the syringe or measuring device supplied with the pack.
Duration Constraint	The product is for short-term use; it should not be given for more than 3 consecutive days without consulting a doctor or pharmacist.

Special Procedural Conditions

Administration is constrained by the rule not to give any other product containing paracetamol concurrently to prevent exceeding the recommended dose. The product is not recommended for children under 6 years of age due to the concentrated strength.

Research evidence / Overview of Studies for Calpol 6 Plus

Evidence for Use in Mild to Moderate Pain Relief

Research has examined this product for outcomes related to physical discomfort, particularly in conditions involving periods of heightened symptoms such as headache, toothache, and earache. Studies conducted to understand the product's use often involve short-term Randomized Controlled Trials (RCTs) and systematic reviews. These trials have monitored changes in pain intensity over defined time intervals, using scales reported by children or their caregivers, to track outcomes describing episodic or acute changes in their discomfort.

The findings describe patterns observed in the studies over the short periods following administration. Research highlights changes measured during the study period related to changes in measured acute pain scores. Some studies reported how symptoms evolved in the observed populations compared to groups receiving an inactive substance or another studied intervention. However, it is important to remember that these findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Evidence for Use in Fever Reduction (Antipyresis)

This product was studied for its use in managing fever, which is one of the conditions characterized by fluctuating or episodic manifestations related to systemic or functional imbalance. The research includes placebo-controlled trials, where some participants received the product and others received an inactive substance, and also trials that compared its use to other studied interventions. These studies primarily monitored changes in body temperature, which are outcomes monitoring physiological strain or stress. The research aimed to observe these changes over several hours.

Understanding Long-Term Studies and Follow-up Data

The available evidence largely reflects research exploring short-term symptom changes and is typically limited to the acute phase of a condition (e.g., the first 4 to 24 hours of pain or fever). Consequently, follow-up durations were limited in many of the primary studies. Long-term effects are not fully established, meaning there is limited information for long-term outcomes regarding the continued or intermittent use of this product over weeks or months.

What Is Still Uncertain About the Research Evidence

Despite the existing body of work, several areas remain insufficiently studied. As noted, long-term effects are not fully established, as follow-up durations were limited. Data are still emerging regarding how the product was observed in children who have multiple health issues, and evidence quality varies across studies. This research describes what is known and what remains unstudied. Study results reflect the specific conditions under which they were conducted.

Key Studies & References

1. Fever in under 5s: assessment and initial management (NICE Guideline NG143)
2. Analgesics and Antipyretics: Paracetamol (Acetaminophen) - Summary of Product Characteristics (SPC) for UK/EU Regulatory Reference

Common questions about Calpol 6 plus (FAQ)

---

Q: How quickly can Calpol 6 plus start to reduce fever or pain?

A: Official regulatory sources indicate that the active ingredient in this medicine starts to act on fever within 15 minutes of administration. The time to reach the full effect can vary. This information describes the general expected action of the drug.

Q: What is the typical time frame for Calpol 6 plus to be fully eliminated from the body?

A: The half-life of the active ingredient, paracetamol, is typically described in authoritative sources as ranging from 1 to 4 hours in individuals with a healthy liver function. The half-life refers to the time it takes for half of the drug to be removed from the bloodstream.

Q: Is it true that Calpol 6 plus is gentler on the stomach compared to some other pain relievers?

A: Official product summaries often describe the product as being 'gentle on the stomach'. This description is based on the active ingredient's known properties as an analgesic and antipyretic.

Q: Is there a maximum recommended age for using Calpol 6 plus?

A: Official administration instructions include dose recommendations for children over 6 years, adolescents, and adults. No explicit upper age limit is defined in the regulatory dose tables.

Q: Is there any specific information about Calpol 6 plus use during pregnancy or breastfeeding for older teens?

A: Official guidance states that use during pregnancy requires consideration of clinical need. Use during lactation (breastfeeding) is not generally contraindicated in regulatory documents.

Q: Does Calpol 6 plus have any known interaction with anti-epileptic drugs?

A: Regulatory documents list several anti-epileptic drugs, such as Carbamazepine and Phenytoin, that may interact with the active ingredient. These interactions can occur by inducing liver enzymes, potentially increasing the risk of toxicity.

Q: Can Calpol 6 plus interact with herbal supplements a child might be taking?

A: Regulatory documents specifically mention the herbal product St. John's Wort as a substance that may interact by inducing liver enzymes. Inducing these enzymes may increase the potential for toxicity from the active ingredient.

Q: Is the Calpol 6 plus suspension sugar-free, and what is the difference between the versions?

A: The official product is designated as Sugar Free Oral Suspension. This formulation uses sweeteners like maltitol and sorbitol instead of sucrose (sugar). Both the sugar-free and non-sugar-free versions contain the same amount of the active ingredient.

Q: Is Calpol 6 plus known to cause drowsiness or make a child sleepy?

A: Drowsiness or sleepiness is not listed as a common or known side effect in the official regulatory adverse reaction tables for this product.

Q: Is it safe to use Calpol 6 plus for pain relief over several days?

A: The official administration constraint states that the product should not be given for more than 3 consecutive days without consulting a doctor or pharmacist. This constraint is detailed in official documents, and the product is intended for short-term, symptomatic use.

Q: Can Calpol 6 plus be used by adults who have difficulty swallowing tablets?

A: Official product leaflets state that this specific oral suspension is suitable for adults who find it easier to use than tablets due to the liquid format.

Q: Can Calpol 6 plus be used for post-immunisation fever in children over 6?

A: Official therapeutic indications for use include providing relief from fever, and specifically list post-immunisation fever as one of the conditions for which the product may be used.

Q: Are there different strengths of Calpol 6 plus suspension available?

A: The official product is available only at one strength for the 6+ age group, which is 250 mg of Paracetamol per 5 mL of suspension. This is the concentration appropriate for older children.

Q: Does Calpol 6 plus contain any alcohol?

A: Some formulations of the product contain a small quantity of ethanol (alcohol). Official warnings note this should be considered for certain high-risk groups, including pregnant or breastfeeding individuals and children, where appropriate.

Q: Can the ingredients in Calpol 6 plus cause an allergic reaction?

A: The product is strictly contraindicated in patients with known hypersensitivity to the active ingredient, paracetamol, or any of its excipients (inactive ingredients). Very rare adverse reactions listed include hypersensitivity and anaphylactic reaction.

Q: What are the excipients (inactive ingredients) in Calpol 6 plus, and what is their purpose?

A: Official documentation lists excipients such as Maltitol, Sorbitol, Glycerol, and Xanthan Gum. These typically serve functions such as sweetening, providing texture, and stabilizing the liquid formulation.

Q: What are the ingredients in Calpol 6 plus that give it a specific flavor or color?

A: The official composition lists specific ingredients, such as imitation strawberry flavouring, that contribute to the taste of the medicine. Some non-sugar-free versions may also contain coloring agents like Sunset Yellow (E110).

Q: Can Calpol 6 plus be used to treat teething pain in an older child?

A: While teething pain is a specific type of pain, the product is indicated for the relief of general pain such as toothache, which may occur in the head and mouth area.

Q: What is the importance of the child's weight when considering Calpol 6 plus?

A: Official administration instructions specify dose volume based on the child's age band (e.g., 6–8 years, 8–10 years), rather than relying on body weight. This is the official protocol for dosing this ready-to-use formulation.

Q: What are the storage requirements for Calpol 6 plus once the bottle is opened?

A: Official storage rules focus on maintaining the product's quality, such as storing it at room temperature (not exceeding 25 °C) and protecting it from light and heat. Since no specific shelf life is typically given for after opening, the product should be used before the expiry date printed on the bottle or carton.

Q: Can a slight increase in tiredness be expected after taking Calpol 6 plus?

A: Tiredness or fatigue is not listed as a common or known side effect in the official regulatory adverse reaction tables for this product.

Q: What is the difference between the oral suspension and the 'Fastmelts' tablet form of Calpol 6 plus?

A: Both forms contain the same active ingredient, paracetamol. The Oral Suspension is a liquid dose, while Fastmelts are a solid form—tablets that dissolve quickly in the mouth for oral administration.

Q: Can Calpol 6 plus be used if a child has a sore throat but no fever?

A: Official indications for use include the symptomatic relief of sore throat, which is a pain condition. The product's use for pain relief is described as independent of whether a fever is also present.

Q: Can other common over-the-counter cold and flu products be used safely alongside Calpol 6 plus?

A: The most crucial safety rule is the strict prohibition against using any other product containing paracetamol (acetaminophen), which is a common ingredient in many cold and flu medicines. Other specific interactions with certain ingredients are also detailed in official documents.

Q: Is there any research about the long-term safety of the ingredients in Calpol 6 plus?

A: The available research evidence largely reflects outcomes observed during short-term symptom changes, and follow-up durations are often limited. Official documents note that long-term effects are not fully established regarding the continued or intermittent use of this product over extended periods.

Q: Can Calpol 6 plus affect the results of any medical tests?

A: Official documentation indicates that the active ingredient, paracetamol, may interfere with the results of certain laboratory tests. These include some blood tests for glucose, urate, bilirubin, and prothrombin time.

Official Storage and Disposal Requirements

Calpol Six Plus Sugar Free Oral Suspension must be stored strictly according to the conditions defined in official regulatory documents to maintain its stability.

Requirement Category	Official Regulatory Rule
Temperature	Store at room temperature, not exceeding 25 °C.
Environment	Must be protected from direct light and heat.
Prohibited Storage	Do not refrigerate or freeze the suspension.
Packaging	Keep the medicine in the original container and do not use past the expiry date.
Child Safety	Must be kept out of the sight and reach of children.

For disposal, unused or expired Calpol Six Plus must not be thrown into household waste or wastewater. The official procedure requires consulting a pharmacist for instructions on how to properly discard the medicine to ensure environmental protection.